Alumis Inc. demonstrated a significant clinical milestone in early 2026 with positive Phase 3 topline results for its lead TYK2 inhibitor, envudeucitinib, targeting moderate-to-severe plaque psoriasis. This breakthrough underpins the company’s transition from clinical development to commercial readiness, supported by ongoing Phase 2 studies and an expanding pipeline including CNS-penetrant compounds and acquired monoclonal antibody assets. Despite considerable operating losses intensifying year-over-year due to R&D investments, Alumis sustains a strong liquidity position and strategic capital allocation to support next-stage growth, although manufacturing dependencies on third-party suppliers introduce operational risks ahead of product launch.